Balchem CORP Form 4 insider transactions

A Balchem Corporation executive reported the acquisition of restricted stock and performance units, alongside shares withheld for tax obligations, and new stock option grants.

Balchem Corporation's SVP Chief Supply Chain Officer, Martin Luther Reid, reported the acquisition of restricted stock and performance units, alongside new stock options, and shares withheld for tax obligations.

Balchem Corporation's Chairman, President & CEO, Theodore L. Harris, reported significant equity awards, including restricted stock, performance units, and stock options, alongside shares withheld for tax obligations.

Balchem Corporation's SVP and Chief R&D Officer, George Graham, reported the acquisition of 700 restricted stock units and 2,600 stock options.

Balchem Corporation's VP & Chief Accounting Officer, William A. Backus, reported the acquisition of restricted stock and performance units, along with stock option grants and shares withheld for tax obligations.

Balchem Corporation's SVP Frederic Boned reported recent equity transactions, including restricted stock grants, performance unit vesting, and stock option awards, alongside tax-related share dispositions.

Balchem's SVP & Chief HR Officer, Michael Brent Tignor, reported the acquisition of restricted stock, performance units, and stock options, alongside share disposals for tax obligations.

Balchem Corporation's EVP, CLO, and Secretary, Hatsuki Miyata, reported the acquisition of restricted stock and performance units, alongside the disposition of shares for tax withholding.

Balchem Corporation's EVP & CFO, Carl Martin Bengtsson, reported significant equity awards and option grants, alongside tax-related share disposals, under a pre-arranged 10b5-1 plan.

Balchem Corporation Director Olivier Rigaud was granted 870 shares of restricted common stock, vesting one year from the grant date.

Balchem Corporation's Director, Daniel E. Knutson, acquired 870 shares of common stock as restricted stock, vesting in one year.

Balchem Corporation Director Kathleen B. Fish acquired 870 shares of common stock as restricted stock, increasing her direct beneficial ownership to 3,429 shares.

Balchem Corporation Director Matthew David Wineinger acquired 870 shares of common stock as restricted stock, vesting in one year.

Balchem Corporation Director David B Fischer acquired 870 shares of common stock as restricted stock, vesting in one year.

Balchem Corporation's Director, Monica Vicente, was granted 870 shares of common stock as restricted stock, vesting one year from the grant date.

Balchem's VP & Chief Accounting Officer, William A. Backus, disposed of 322 shares of common stock to cover tax liabilities upon restricted stock vesting.

Balchem Corporation's EVP, CLO, and Secretary, Hatsuki Miyata, reported a routine disposition of 343 common shares to cover tax liabilities from restricted stock vesting.

Balchem Corporation's SVP and GM of Specialty Products, Job Leonard van Gunsteren, reported the withholding of 258 common shares to cover tax obligations upon the vesting of restricted stock.

Balchem Corporation's VP & Chief Accounting Officer, William A. Backus, filed a late Form 4 disclosing the withholding of 383 shares for tax obligations related to restricted stock vesting.

Balchem Corporation's Chairman, President & CEO, Theodore L Harris, reported a disposition of shares to cover tax obligations related to restricted stock vesting.

Balchem's SVP/GM, Human Nutrition & Health, Frederic Boned, disposed of 430 shares of common stock to cover tax withholdings related to restricted stock vesting.

Balchem's SVP Chief Supply Chain Officer, Martin Luther Reid, disposed of 416 common shares to cover tax withholdings related to restricted stock vesting.

Balchem Corporation Director David B. Fischer exercised stock options and subsequently sold a portion of his common stock holdings on December 3, 2025.

Balchem's SVP and GM of Specialty Products, Job Leonard van Gunsteren, exercised stock options and subsequently sold a portion of his common stock holdings.

Balchem Corporation's SVP Chief Supply Chain Officer, Martin Luther Reid, reported the sale of 1,200 shares of common stock at $154.44 per share.

Frederic Boned, SVP/GM at Balchem Corp, disposed of 1,085 shares of common stock to cover tax withholdings related to restricted stock vesting.

George Graham, SVP and Chief R&D Officer of Balchem Corp, acquired 2,500 shares of common stock as restricted stock, vesting over three years.

Balchem Corporation's EVP, CLO, and Secretary, Hatsuki Miyata, reported the disposition of shares for tax withholding and the acquisition of shares through the company's 401(k) plan.

Olivier Rigaud, a director at Balchem Corp, filed an amended SEC Form 4/A to correct the vesting period of restricted stock from three years to one year.

David B Fischer, a director at Balchem Corp, filed an amended SEC Form 4/A to correct the vesting period of restricted stock from 3 years to 1 year.